ALT Altimmune Inc

Price (delayed)

$10.29

Market cap

$444.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.41

Enterprise value

$264.75M

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), ...

Highlights
Altimmune's net income has shrunk by 69% YoY and by 4.7% QoQ
ALT's quick ratio has shrunk by 60% YoY and by 10% QoQ

Key stats

What are the main financial stats of ALT
Market
Shares outstanding
43.22M
Market cap
$444.73M
Enterprise value
$264.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
125.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.44
Earnings
Revenue
$3.6M
EBIT
-$101.6M
EBITDA
-$101M
Free cash flow
-$80.11M
Per share
EPS
-$2.41
Free cash flow per share
-$1.82
Book value per share
$4.28
Revenue per share
$0.08
TBVPS
$4.39
Balance sheet
Total assets
$205.66M
Total liabilities
$20.79M
Debt
$0
Equity
$184.87M
Working capital
$171.97M
Liquidity
Debt to equity
0
Current ratio
9.99
Quick ratio
9.42
Net debt/EBITDA
1.78
Margins
EBITDA margin
-2,801.9%
Gross margin
100%
Net margin
-2,820%
Operating margin
-2,817.1%
Efficiency
Return on assets
-44.3%
Return on equity
-48.7%
Return on invested capital
-490%
Return on capital employed
-54.5%
Return on sales
-2,818.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALT stock price

How has the Altimmune stock price performed over time
Intraday
-2.92%
1 week
14.08%
1 month
118.01%
1 year
-36.48%
YTD
12.34%
QTD
68.97%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$3.6M
Gross profit
$3.6M
Operating income
-$101.55M
Net income
-$101.66M
Gross margin
100%
Net margin
-2,820%
Altimmune's net income has shrunk by 69% YoY and by 4.7% QoQ
Altimmune's operating income has plunged by 63% YoY and by 4.8% from the previous quarter
ALT's revenue is down by 47% year-on-year and by 18% since the previous quarter
The gross profit has contracted by 47% YoY and by 18% from the previous quarter

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
2.41
P/S
125.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
73.44
Altimmune's EPS has decreased by 19% YoY and by 2.6% QoQ
The P/B is 119% higher than the 5-year quarterly average of 1.1 and 42% higher than the last 4 quarters average of 1.7
The equity has declined by 25% year-on-year and by 7% since the previous quarter
ALT's revenue is down by 47% year-on-year and by 18% since the previous quarter
ALT's P/S is 39% above its last 4 quarters average of 90.3

Efficiency

How efficient is Altimmune business performance
The company's return on invested capital has shrunk by 128% QoQ
ALT's ROA has shrunk by 56% YoY and by 12% QoQ
The return on equity has dropped by 53% year-on-year and by 12% since the previous quarter
Altimmune's return on sales has decreased by 28% QoQ

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Altimmune financials performed over time
Altimmune's current ratio has plunged by 60% YoY and by 11% from the previous quarter
ALT's quick ratio has shrunk by 60% YoY and by 10% QoQ
The debt is 100% smaller than the equity
The equity has declined by 25% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.